العقود الآجلة
وصول إلى مئات العقود الدائمة
TradFi
الذهب
منصّة واحدة للأصول التقليدية العالمية
الخیارات المتاحة
Hot
تداول خيارات الفانيلا على الطريقة الأوروبية
الحساب الموحد
زيادة كفاءة رأس المال إلى أقصى حد
التداول التجريبي
مقدمة حول تداول العقود الآجلة
استعد لتداول العقود الآجلة
أحداث مستقبلية
"انضم إلى الفعاليات لكسب المكافآت "
التداول التجريبي
استخدم الأموال الافتراضية لتجربة التداول بدون مخاطر
إطلاق
CandyDrop
اجمع الحلوى لتحصل على توزيعات مجانية.
منصة الإطلاق
-التخزين السريع، واربح رموزًا مميزة جديدة محتملة!
HODLer Airdrop
احتفظ بـ GT واحصل على توزيعات مجانية ضخمة مجانًا
منصة الإطلاق
كن من الأوائل في الانضمام إلى مشروع التوكن الكبير القادم
نقاط Alpha
تداول الأصول على السلسلة واكسب التوزيعات المجانية
نقاط العقود الآجلة
اكسب نقاط العقود الآجلة وطالب بمكافآت التوزيع المجاني
3 European Stocks Estimated To Be Up To 49.8% Below Intrinsic Value
3 European Stocks Estimated To Be Up To 49.8% Below Intrinsic Value
Simply Wall St
Fri, February 13, 2026 at 2:38 PM GMT+9 4 min read
In this article:
TLGO.MC
-1.37%
IVSO.ST
+27.52%
SNG.RO
+5.12%
GALDY
+0.98%
^GDAXI
-0.01%
As the European markets continue to show resilience amid global volatility, optimism about the eurozone economy has supported investor sentiment, with major indices like Germany’s DAX and France’s CAC 40 posting gains. In this environment of cautious optimism and stable interest rates from the European Central Bank, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market opportunities.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Click here to see the full list of 199 stocks from our Undervalued European Stocks Based On Cash Flows screener.
We’re going to check out a few of the best picks from our screener tool.
SNGN Romgaz
Overview: SNGN Romgaz SA is engaged in the exploration, production, and supply of natural gas in Romania, with a market capitalization of RON44.32 billion.
Operations: The company’s revenue is primarily derived from its upstream operations, which account for RON7.85 billion, followed by storage services at RON614.59 million and electricity production at RON485.92 million.
Estimated Discount To Fair Value: 23.2%
SNGN Romgaz is trading at a value 23.2% below its estimated fair value and significantly under its future cash flow valuation of RON14.97, with current trading at RON11.5. Its earnings grew by 15.4% last year, and revenue growth is expected to outpace the regional market at 11.3% per year compared to 4.8%. Recent earnings showed increased net income for Q3 and nine months ending September 2025, indicating robust financial health despite high non-cash earnings levels.
BVB:SNG Discounted Cash Flow as at Feb 2026
Invisio
Overview: Invisio AB (publ) develops and sells communication and hearing protection systems for defense, law enforcement, and security professionals globally, with a market cap of approximately SEK14.87 billion.
Operations: The company’s revenue primarily comes from the Aerospace & Defense segment, which generated SEK1.65 billion.
Estimated Discount To Fair Value: 25.8%
Invisio is trading at SEK322, significantly below its estimated future cash flow value of SEK434.19, suggesting it may be undervalued. The company forecasts robust earnings growth of 44.3% annually over the next three years, outpacing the Swedish market’s 9.3%. Despite recent share price volatility, Invisio’s strategic management changes aim to enhance revenue growth and capitalize on market opportunities, potentially improving financial performance in a dynamic environment.
OM:IVSO Discounted Cash Flow as at Feb 2026
Galderma Group
Overview: Galderma Group AG is a global dermatology company with a market cap of CHF35.73 billion.
Operations: The company generates revenue of $4.69 billion from its dermatology segment.
Estimated Discount To Fair Value: 49.8%
Galderma Group, trading at CHF150.5, is priced considerably below its estimated future cash flow value of CHF299.95, indicating potential undervaluation. The company has recently launched innovative products like Restylane Defyne and Refyne in Japan and received FDA acceptance for RelabotulinumtoxinA in the U.S., enhancing its aesthetic portfolio. Despite lower forecasted revenue growth compared to the broader market, Galderma’s earnings are expected to grow significantly at 26.9% annually over the next three years.
SWX:GALD Discounted Cash Flow as at Feb 2026
Taking Advantage
Contemplating Other Strategies?
_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._
Companies discussed in this article include BVB:SNG OM:IVSO and SWX:GALD.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_
Terms and Privacy Policy
Privacy Dashboard
More Info